NOI for InvivoScribe IGH+IGK Clonality Mega-ABI Assays 75N91026Q00007
Summary
AI-generated · Feb 13, 2026Intent to award a sole-source contract for InvivoScribe IGH+IGK Clonality Mega-ABI Assays to InvivoScribe; this is not a competitive procurement and is conducted under 10 USC 2304(c)(1) and FAR 6.302-1.
InvivoScribe is currently the only provider offering the specific IGH/IGK kit required to support the National Cancer Institute’s molecular laboratories across the Clinical Center protocols.
NOTICE OF INTENT TO AWARD SOLE SOURCE THIS IS NOT A REQUEST FOR COMPETITIVE PROPOSALS. This is a notice of intent to solicit and award a sole source contract under statutory authority 10 USC 2304(c)(1), set forth in Federal Acquisition Regulation 6.302-1, Only One Responsible Source and No Other Supplies or Services Will Satisfy Agency Requirements. The Government intends to solicit and award a sole source contract for InvivoScribe IGH+IGK Clonality Mega-ABI Assays to InvivoScribe. InvivoScribe is currently the only provider that carries the specific required IGH/ IGK kit that fits the need of NCI's molecular laboratories servicing the many protocols of the Clinical Center.
From Special Notice posted on Feb 12, 2026Notice history
1Details
Award Information
Not yet awarded
Contacts
Agency
Place of Performance
USA